7 July 2015: Sharp Clinical Services, part of UDG Healthcare plc, (LON: UDG), the leading international provider of healthcare services, has expanded its storage and packaging facilities in the UK by an additional 5,000 square feet, creating an additional 10 roles at the site. The new facility based in Crickhowell is now the fourth unit of the existing Waller House building and comprises of 150 additional pallet spaces and two assembly lines. The Company’s investment is in response to new product introductions approved by the regulatory authorities.
Sharp Clinical Services is a leading provider of specialist clinical supply chain services to both large pharmaceutical and small biotech companies in the UK and US, from drug product development, analytical and manufacturing services through to increasingly complex clinical trial supplies packaging, clinical labeling and clinical distribution services. Sharp Clinical Services has a proven track record in managing the entire clinical supply chain and has a Global Depot Network of 18 depots supporting over 25 countries.
Ian Morgan, General Manager of Sharp Clinical Services UK, commented on the expansion: “The expansion of the Crickhowell facility is a landmark moment for Sharp Clinical Services in the UK, and enables us to deliver excellent, high quality service to our existing and new customers as demand for our services increases in the UK. The first commercial test ran at the end of May and full production will begin in July.”
Frank Lis, President of Sharp Clinical Services added: “This expansion has increased our global footprint and will allow us to provide our customers with a full range of services, from formulation development and pre-clinical supplies through to product launch.”
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
2 Commerce Drive
Cranbury, NJ 08512